Roche Holding AG, of Basel, Switzerland, is the first company with an FDA-approved, blood-based genetic test to detect a gene mutation associated with the most common type of lung cancer. The agency approved the cobas EGFR Mutation Test v2 as a companion diagnostic for the cancer drug Tarceva (erlotinib).